Sotera Health (NASDAQ:SHC) Shares Purchased by Mudita Advisors LLP

Mudita Advisors LLP lifted its stake in shares of Sotera Health (NASDAQ:SHC) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 406,329 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Sotera Health accounts for about 3.7% of Mudita Advisors LLP’s portfolio, making the stock its 10th largest position. Mudita Advisors LLP’s holdings in Sotera Health were worth $6,786,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of SHC. FMR LLC grew its position in Sotera Health by 259.9% during the 3rd quarter. FMR LLC now owns 32,483 shares of the company’s stock worth $542,000 after acquiring an additional 23,457 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Sotera Health by 11.4% during the third quarter. The Manufacturers Life Insurance Company now owns 128,222 shares of the company’s stock valued at $2,141,000 after purchasing an additional 13,157 shares in the last quarter. Cerity Partners LLC bought a new stake in shares of Sotera Health during the third quarter worth about $1,489,000. Sessa Capital IM L.P. increased its stake in shares of Sotera Health by 46.5% in the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock valued at $105,220,000 after buying an additional 2,000,000 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Sotera Health by 18.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,348,917 shares of the company’s stock valued at $22,527,000 after buying an additional 208,914 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. This represents a 16.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 55.12% of the company’s stock.

Sotera Health Trading Down 2.6 %

NASDAQ:SHC opened at $12.95 on Wednesday. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The firm’s fifty day moving average is $15.46 and its 200-day moving average is $14.01. The firm has a market cap of $3.67 billion, a P/E ratio of 51.80 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same period last year, the company posted $0.18 EPS. The business’s revenue was up 8.5% compared to the same quarter last year. Equities analysts expect that Sotera Health will post 0.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on SHC shares. Citigroup boosted their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.50.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.